USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
CRYSTAL BIOSCIENCE, INC.
Address:
5980 Horton Street Suite 405
EMERYVILLE, CA 94618
EIN:
262851162
DUNS:
827377933
Number of Employees:
23
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $367,283.00 2
SBIR Phase II $1,805,815.00 1

Award List:

Engineered proteins from transgenic animals

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$172,499.00
Agency:
HHS
Principal Investigator:
Robert Etches
Abstract:
DESCRIPTION (provided by applicant): Approximately 25% of the products being developed by the biotechnology industry are antibodies and many of these antibodies are directed to epitopes on human cells and tissues. We are proposing a novel concept for the p roduction of antibodies with therapeutic… More

Engineered proteins from transgenic animals

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,805,815.00
Agency:
HHS
Principal Investigator:
Philip Leighton – 510-768-7758
Abstract:
DESCRIPTION (provided by applicant): Approximately 25% of the products being developed by the biotechnology industry are antibodies and many of these antibodies are directed to epitopes on human cells and tissues. We are proposing a novel concept for the production of antibodies with therapeutic… More

Novel therapeutic antibodies for the treatment and prevention of AIDS

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$194,784.00
Agency:
HHS
Principal Investigator:
Bill D. Harriman – 510-250-7797
Abstract:
DESCRIPTION (provided by applicant): We seek to capitalize on a substantial body of work has characterized the immune responses of HIV+ individuals with very slow disease progression (LTNP), and HIV- individuals who do not seroconvert despite repeated HIVexposure (ESN). A fraction of people in these… More